Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KSH1
- Development stage
- Preclinical
- Lead developer
- Baku State University
- Modality
- Small Molecules
01
Overview
KSH1 is an experimental small molecule chalcone derivative developed as a potential antibacterial agent [O0289]. Synthesized via a Claisen-Schmidt condensation reaction, KSH1 features a nitro (NO2) group at the meta or para position, which has been shown to enhance its antibacterial spectrum [O0289]. In preclinical studies, KSH1 demonstrated potent antibacterial activity against clinical isolates of *Staphylococcus aureus*, including multidrug-resistant strains, with minimum inhibitory concentration (MIC) values ranging from 2 to 16 µg/mL [O0289]. Additionally, KSH1 exhibits strong biofilm eradication properties, achieving 75% biofilm inhibition at a concentration of 2 µg/mL [O0289].
Beyond the preview
Go deeper on KSH1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KSH1.